Novartis: The combination of Tantexi single-target antibody and Lenadurine for the treatment of r/rDLBCL has been approved.

Nuochengjianhua announcement, the company's CD19-targeted product Tantiuxi monoclonal antibody combined with lenalidomide for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma who are not suitable for autologous stem cell transplantation has been approved by the National Medical Products Administration. This is the first CD19 monoclonal antibody approved in China for the treatment of r/r DLBCL.